Article
Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
2026-03-13
Abstract excerpt
<title>Abstract</title> <p> <bold>Background</bold> Epcoritamab, a subcutaneous CD3×CD20 bispecific antibody, has demonstrated promising activity in relapsed or refractory diffuse large B‑cell lymphoma. Cytokine release syndrome is a key adverse event associated with T‑cell–engaging therapies; however, it typically occurs early after treatment initiation and is generally manageable with step‑up dosing and preme...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0bb7339e-4a35-555a-aa37-d4e7e8cc253e
- DOI
- 10.21203/rs.3.rs-9059446/v1
